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Abstract 
Background: Heart failure (HF) and diabetes (DM) are a lethal combination. The current armamentarium of anti-dia-
betic agents has been shown to be less efficacious and sometimes even harmful in diabetic patients with concomi-
tant cardiovascular disease, especially HF. Sodium glucose linked co-transporter type 2 (SGLT2) inhibitors are a new 
class of anti-diabetic agent that has shown potentially beneficial cardiovascular effects such as pre-load and after load 
reduction through osmotic diuresis, blood pressure reduction, reduced arterial stiffness and weight loss. This has been 
supported by the recently published EMPA-REG trial which showed a striking 38 and 35 % reduction in cardiovascular 
death and HF hospitalisation respectively.
Methods: The REFORM trial is a novel, phase IV randomised, double blind, placebo controlled clinical trial that has 
been ongoing since March 2015. It is designed specifically to test the safety and efficacy of the SLGT2 inhibitor, 
dapagliflozin, on diabetic patients with known HF. We utilise cardiac-MRI, cardio-pulmonary exercise testing, body 
composition analysis and other tests to quantify the cardiovascular and systemic effects of dapagliflozin 10 mg once 
daily against standard of care over a 1 year observation period. The primary outcome is to detect the change in left 
ventricular (LV) end systolic and LV end diastolic volumes. The secondary outcome measures include LV ejection frac-
tion, LV mass index, exercise tolerance, fluid status, quality of life measures and others.
Conclusions: This trial will be able to determine if SGLT2 inhibitor therapy produces potentially beneficial effects in 
patients with DM and HF, thereby replacing current medications as the drug of choice when treating patients with 
both DM and HF.
Trial registration Clinical Trials.gov: NCT02397421. Registered 12th March 2015
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Background
Heart failure (HF) is a growing global pandemic with a 
14 % increase in prevalence from 1990 to a staggering 41 
million patients worldwide in 2010 [1]. With improving 
acute cardiovascular outcomes and longer life expec-
tancy, this number will rise further. HF is already one of 
the leading causes of hospitalisation in elderly patients 
[2]. This translates to a burgeoning financial burden on 
the healthcare system; costing $39.2 billion in the US 
alone in 2010 [3].
HF is associated with numerous co-morbidities that 
can contribute to the progression of the disease and may 
alter the response to therapy [4]. One important co-
morbidity of HF is diabetes mellitus (DM). In population 
based studies and in HF trials, the prevalence of type 2 
DM among patients with symptomatic HF is estimated to 
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be between 12 and 49 % [5, 6]. Among all patients hospi-
talized for HF, it has been reported that up to 40 % have 
type 2 DM [7, 8]. This association can be lethal since DM 
has consistently been shown to be an independent pre-
dictor of increased morbidity and mortality in patients 
with HF; [9] patients with DM and HF have a median 
survival of 4  years [10]. However, treating patients with 
these concomitant diseases can be challenging.
Treating heart failure and diabetes
In the treatment of DM, EASD/ADA guidelines recom-
mend tailoring therapeutic approaches to individual needs 
and/or risks [11]. For most patients, metformin is the first 
choice anti-diabetic drug in type 2 DM including those with 
HF. In 2010, investigators reported potential benefits of 
metformin therapy in HF in DM in the Scottish population 
[12], a finding that has since been confirmed by others [13, 
14]. However, metformin alone is often not enough to keep 
glycaemia under control and there frequently is a need for a 
second line anti-diabetic drug in patients with HF and DM. 
However, the choices for patients with concomitant HF are 
very limited; sulphonylureas (SU) are agents that are com-
monly prescribed in DM but are associated with weight 
gain and hypoglycaemia which are detrimental in heart fail-
ure [15, 16]. Moreover, there remain concerns that SUs may 
increase all-cause and CV-mortality [17], although this link 
is not fully established. Glitazones are contra-indicated in 
New York Heart Association functional class (NYHA) III 
or IV HF, while their role in milder degrees of HF remain 
somewhat controversial with a few observational studies 
indicating increased HF hospitalisation [18]. More recent 
agents such as DPPIV inhibitors have also failed to show 
cardiovascular benefit; TECOS showed sitagliptin had a 
neutral effect on cardiovascular outcomes [19]. Similarly 
EXAMINE revealed alogliptin had no effect on major 
adverse CV events (MACE) among diabetic patients with 
recent ACS [20]. While SAVOR-TIMI-53 revealed that 
saxagliptin increased HF hospitalisations [21]. Therefore, 
we can conclude that second line therapeutic options in 
DM and HF are very limited and there is a critical need for 
agents that will both improve glycaemic control as well as 
HF outcomes.
Sodium glucose linked co‑transporter 2 (SLGT2) inhibitors 
and the heart
SGLT2 inhibitors employ a novel mechanism to lower 
blood glucose by preventing the reabsorption of glucose 
in the renal tubules. There are currently 3 agents that 
have been licenced for clinical use; dapagliflozin, empa-
gliflozin and canagliflozin. By competitively blocking 
the SGLT2 receptors in the proximal convoluted tubules 
(PCT), SGLT2 inhibitors prevent the reabsorption of 
filtered sodium and glucose, resulting in glycosuria and 
natriuresis [22, 23] (Fig.  1). This novel mechanism of 
action means SGLT2 inhibitors function independently 
of insulin levels, pancreatic function and degree of insu-
lin resistance. Accordingly, this class of drug is expected 
to continue to maintain its potency as beta cell function 
deteriorate along with disease progression—a key feature 
that is not seen in other oral anti-diabetic drug classes 
[24]. Another distinctive feature of SGLT2 inhibitors is 
its low hypoglycaemic risk. By limiting its activity to uri-
nary glucose excretion, SGLT2 inhibitors do not stimu-
late insulin release [25] or interfere with the physiologic 
response to hypoglycaemia [26].
The additional natriuretic effect (and resultant osmotic 
diuresis) of SGLT2 inhibitors could potentially be ben-
eficial in patients with cardiovascular disease, especially 
those with HF, thereby distinguishing SGLT2-inhibi-
tors from all the other oral anti-diabetic agents. Indeed 
SGLT2-ihibitors have been shown to have a number of 
positive cardiovascular effects on top of their glycae-
mic effects. This class of drug has been shown to lower 
blood pressure (by 7–10 mmHg) [27, 28], reduce arterial 
stiffness [29], reduce urinary microalbuminuria [30] (a 
marker of CV risk) and reduce triglycerides and increase 
HDL and LDL cholesterol (without altering HDL/LDL 
ratios) [24].
Recently, the EMPA-REG Outcomes trial had dem-
onstrated a remarkable reduction in CV mortality and 
HF hospitalisations, by 38 and 35  % respectively, among 
patients with high CV risk who were treated with empagli-
flozin [31]. Further analysis of the data suggested that this 
benefit was consistent in patients with or without HF at 
baseline [32]. However, it is important to note that EMPA-
REG Outcomes studied a broad range of CV risk patients 
and only 10 % had HF at baseline, thus raising the possibil-
ity the outcomes seen in this group be due to chance. Nev-
ertheless, such striking results warrants further inquiry. 
Interestingly, separation of the event curves in EMPA-REG 
outcomes were seen very early—within 3  months—lead-
ing some to speculate that the osmotic diuresis effect of 
SGLT2-inhibitors was responsible for this, as its effect 
other mechanisms such as LV remodelling and atheroscle-
rosis would have taken longer to manifest. However, there 
has yet to be a mechanistic trial to test this hypothesis. As 
we specify below, the REFORM Trial will rigorously test 
the mechanisms behind the potential cardiovascular ben-
efits of the SGLT2-inhibitor, dapagliflozin, specifically in 
the diabetic heart failure population.
Methods
Study design
The REFORM trial is a randomised, double blinded, 
placebo controlled single-centre study conducted in 
NHS tayside, Scotland to compare the SGLT2 inhibitor, 
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dapagliflozin 10 mg to placebo (standard of care). A recruit-
ment window of 1.5  years has been set between March 
2015 and August 2016. Participants will be enrolled in this 
trial for a period of between 12 to 13 months, (Fig. 2) there-
fore the overall trial end date will be August 2017.
At the screening visit an initial medical history 
and clinical examination will be performed following 
informed consent. Participants will have bloods taken 
for safety analysis and vital signs recorded to confirm eli-
gibility prior to enrolment. Should the participant meet 
the inclusion criteria and have no exclusions identified 
they will return for a cardiac magnetic resonance imag-
ing (MRI) scan at the Clinical Research Centre, Ninewells 
Hospital, Dundee, within 4 weeks of the planned baseline 
(randomization) visit. At the randomization visit par-
ticipants will complete a 6  min walk test, quality of life 
measures, vital signs, body composition analysis (BCA) 
and cardio-pulmonary exercise test (CPEX) measure-
ments taken. During this visit, participants will also 
be randomly assigned to either Dapagliflozin 10  mg or 
matching placebo. The first dose will be administered at 
this visit and participants will be educated on the symp-
toms of hypoglycaemia and given a written action plan 
on how to manage it in the event it occurs. Patients on 
insulin will have their total daily dose reduced by 10  % 
and given a 2-week glucose monitoring chart with writ-
ten instructions to self-manage their insulin doses. This 
will be reviewed by the research team at the next visit.
Participants will return 2 weeks later for a short safety 
visit where they will have safety and BNP bloods, insulin 
dose (if applicable), adverse events and vital signs moni-
tored. This will be followed by 2 more visits on months 2 
and 6 with the same agenda. Three telephone visits are 
planned in the study schedule, at week 4, months 4 and 
9. These calls will enable the research team to follow up 
on changes in concomitant medications, adverse events 
and to remind the participant of study drug compliance. 
Participants will continue with all their usual medica-
tions, these remain unchanged throughout unless clini-
cally indicated. If any titration of a participant’s other 
medications (i.e. anti-diabetic agents or diuretic agents) 
is indicated these changes will be done, in consultation 
with their general practitioners (GP), and the changes 
recorded for analysis later.
At the end of the 1 year study period, participants will 
return for a repeat assessment of the 6  min walk test, 
quality of life measures, BCA, CPEX and cardiac MRI. 
These values will be compared to their baseline tests to 
determine if any significant change has occurred with 
each of the two arms of the study populations. (See 
Table  1 for an overview of all visits scheduled for the 
trial).
Study population
We will employ a two-pronged recruitment process. 
Firstly, we will identify potential patients from the local 
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♦90% GLUCOSE RESORBED 
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Fig. 1 Normal renal tubular resorption of glucose. The figure above depicts the physiological resorption of glucose in the PCT of the nephron. 
SGLT2 co-transporters located at the S1 and S2 segments of the PCT are responsible for 90 % of the resorbed glucose, whereas SGLT1 co-transport-
ers remove the remainder in the S3 segment. The diagram also identifies the site at which SGLT2 inhibitors act. PCT proximal convoluted tubules
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tayside pool of the systems biology study to tailored 
treatment in chronic heart failure (BIOSTAT) data-
base consisting of around 1800 patients with HF who 
have previously consented to be approached for future 
research. We will also identify patients from the Scottish 
Primary Care Research Network (SPCRN), SHARE The 
Scottish Health Research Register, Generation Scotland 
Database, Scottish Diabetes Research Network and Well-
come Study Database. Secondly, we will also allow oppor-
tunistic recruitment from the various cardiovascular and 
HF clinics as well as from the cardiac rehabilitation pro-
gram conducted in Ninewells Hospital. All these sources 
should provide a sufficient pool of diabetic HF patients to 
be recruited into the trial.
Eligibility
All potential participants who meet the following inclu-
sion and exclusion criteria will be eligible for the trial:
Inclusion criteria:
  • Aged 18–75  years were previously diagnosed with 
type 2 DM.
  • Diagnosed with NYHA functional I–III HF with 
prior echocardiographic evidence of left ventricular 
Fig. 2 Study design flowchart. HF Heart failure; LVESV Left ventricular end systolic volume; LVEDV Left ventricular end diastolic volume; LV Left ven-
tricular; LVEF Left ventricular ejection fraction; MRI Magnetic resonance imaging; QOL Quality of life
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systolic dysfunction (LVSD) (ejection fraction <45 % 
or subjective assessment of LV dysfunction that is 
mild or worse).
  • On furosemide 80 mg daily or less, or equivalent loop 
diuretic.
  • Have stable HF symptoms for at least 3 months prior 
to consent.
  • On stable therapy for HF for at least 3 months prior 
to consent.
  • Have not been hospitalised for HF for at least 
3 months prior to consent.
Exclusion criteria:
  • Severe hepatic disease.
  • Renal disease defined as CKD stage 3b or worse (i.e. 
eGFR <45 ml/min).
  • Systolic BP <95 mmHg at screening visit.
  • Screening HbA1c <6.0 %.
  • Unable to walk or to perform cardio pulmonary exer-
cise testing or 6MWT.
  • Malignancy (receiving active treatment) or other life 
threatening diseases.
  • Pregnant or lactating women.
  • Any contraindication to MRI (e.g. claustrophobia, 
metal implants, penetrative eye injury or exposure to 
metal fragments in eye requiring medical attention).
  • Patients who have participated in any other clinical 
trial of an investigational medicinal product within 
the previous 30 days.
  • Patients who are unable to give informed consent.
  • Any other reason considered by a study physician to 
be inappropriate for inclusion.
Randomisation and treatment allocation
After successful screening for eligibility and safety, par-
ticipants will be randomised to either dapagliflozin 
10  mg or matching placebo (microcrystalline cellulose 
Ph Eur overencapsulated in a hard gelatine capsule shell) 
in a double blind fashion. The double blind medication 
(dapagliflozin or placebo) will be prepared, packaged 
and labelled by our onsite clinical trials pharmaceutical 
manufacturer. Randomisation will be carried out by our 
dedicated clinical trials pharmacy using block randomi-
sation. They will use a validated randomisation program 
and will securely backup both the randomisation seed 
and the randomisation allocation and have it available in 
the onsite 24-h emergency unblinding facility.
Once randomised, the participant will continue tak-
ing the trial medication once daily for 1 year, if tolerated. 
Compliance will be checked and documented, by the 
dispensing pharmacy, using tablet counts at each visit. 
If non-compliant, they will be encouraged to become 
compliant. If study drug needs to be stopped due to intol-
erance or adverse events, they will remain in the study in 
order to do an “intention to treat” analysis.
Study outcomes
Primary outcomes
The primary outcome is to determine if dapagliflozin 
induces a change in LV end systolic volume (ESV) or LV 
end diastolic volume (EDV) in patients with DM associ-
ated HF when compared to placebo.
Secondary outcomes
  • To determine if there is a change in LV mass, LV 
ejection fraction (EF), right ventricular (RV) EDV, 
RV ESV, RV EF, atrial dimensions and volumes, and 
LV remodelling index (RI) (LV mass/LVEDV) with 
dapagliflozin in DM associated HF compared with 
placebo.
  • To determine if there is a change in BCA as a meas-
ure of fluid status with dapagliflozin in DM associ-
ated HF compared with placebo.
  • To determine if dapagliflozin can improve exercise 
tolerance in DM patients with HF as measured by pre 
and post 6 min walk test and CPEX.
  • To determine if there are patient reported improve-
ments in quality of life with dapagliflozin compared 
to placebo as measured by the Minnesota Living with 
Heart Failure Questionnaire and SF-36 questionnaire.
  • To determine the effect of dapagliflozin on BNP, 
markers of inflammation and oxidative stress (IL-6, 
F2-isoprostane, HS-CRP and Oxidised LDL).
  • To determine if dapagliflozin use results in any 
change in diuretic dose among patients with DM and 
HF.
  • To determine if dapagliflozin reduces microalbumi-
nuria in patients with DM and HF.
  • To determine if dapagliflozin increases natriuresis in 
patients with DM and HF.
  • To assess the safety of dapagliflozin in DM associated 
HF.
Sample size and power calculations
Improvements in LV volumes have stood out as a marker 
that most strongly correlates with the impact of a drug/
device therapy on improving heart failure survival [33]. 
Grothues et al. [34] suggests that a 10 mL change in LV 
EDV and LV ESV is clinically significant. In a population 
of HF patients the SD for the mean difference of LV EDV 
and LV ESV has been demonstrated to be 7.6 and 7.4 
respectively [34]. Therefore, to detect a 10 mL change in 
EDV and ESV (primary endpoint) with 90 % power and α 
error (p value) of 0.05, a sample size of 13 and 12 respec-
tively is required per arm.
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LV mass is also an important determinant of survival 
in patients with HF [33] and a 10 g reduction in LV mass 
has been shown to be clinically meaningful [34]. It was 
also determined that the SD for 10  g mean change in 
LV mass in the HF population is 9.6 using cardiac MRI, 
implying 20 patients are required per arm [34].
The change in LV EF which best discriminated between 
drugs with positive and neutral effects on mortality 
was 3  % [35]. This is also the figure recommended by 
Grothues as the LV EF change which should be used to 
power studies [34]. Furthermore, Kramer et  al. demon-
strated a 3 % change in LV EF was associated with a 20 % 
improvement in mortality [35]. Our previous MRI expe-
rience have shown an in-house and published SD of the 
change in LV EF within individuals over time as 3.75  % 
for both active and placebo therapies [36]. Therefore in 
order to have 80  % power at p  <  0.05 to detect a ≥3  % 
change in LV EF in a parallel group study, 26 patients per 
group are needed.
As this is a discovery trial, we aim to ensure the trial 
is adequately powered to detect all the clinically relevant 
markers of LV remodelling (LV ejection function, mass 
and volume). Therefore 52 patients will be recruited (26 
patients per arm) to provide at least 80 % power (α error 
0.05) to detect clinically significant changes in LV EDV, 
LV ESV, LV mass and LV EF.
Cardiac MRI protocol
Baseline and repeat CMRI examinations in screen-
ing (±2 weeks before randomisation) and after the final 
12  month (±2  weeks) visit will be performed on a 3T 
Magnetom scanners (Siemens, Erlangen, Germany) using 
body array cardiac and spine matrix radiofrequency coils. 
Analysis will be performed offline (Argus Software, Sie-
mens) by a single blinded observer for the assessment 
of atrial and ventricular volumes and dimensions, EF, 
ventricular mass and LV remodelling index. This single 
observer will analyse all the scans.
The reproducibility of all parameters using MRI will 
be derived for this observer. A test–retest intra-observer 
coefficient of variation of 2.0  % is usual in this depart-
ment’s past MRI studies. Should the scanner become 
unavailable for a prolonged period of time during the 
study an alternative scanner will be used. MRI methods 
will be adapted as appropriate to ensure optimal study 
results can be obtained
Discussion
In this study we propose that there may be unique fea-
tures of SGLT2 inhibitors that result in a number of 
haemodynamic and metabolic effects that can ultimately 
improve survival of patients with HF and DM (Fig. 3).
The primary haemodynamic effect of SGLT2 inhibitors 
is osmotic diuresis. Approximately 375 ml of extra urine 
per day is produced in diabetic patients treated with 
dapagliflozin [24]. Empagliflozin has also been shown 
to modestly increase urinary volumes among patients 
with type 1 DM and hyperfiltrating kidneys [37]. The 
key question is whether or not SGLT2 inhibitors will 
maintain their diuretic properties in HF patients who 
are already on loop diuretic therapy and have impaired 
renal function. A recent meta-analysis of 5 clinical trials 
showed dapagliflozin 10  mg produced clinically mean-
ingful reductions in HbA1c, weight and systolic BP in HF 
patients over a 1 year follow up period [38]. Additionally, 
SGLT2 inhibitors also reduce blood pressure by reduc-
ing arterial stiffness [29], and indirectly, as a result of 
increased diuresis [39, 40]. These effects on intravascular 
volume and blood pressure will result in reduced preload 
and afterload respectively, thereby facilitating the posi-
tive remodelling of the heart [41, 42].
This effect of SGLT2 inhibitors on positive LV remodel-
ling will have major implications on morbidity and mor-
tality in patients with DM and HF. Indeed, a drug’s effect 
on LV remodelling is the best surrogate marker of its effi-
cacy and its impact on hard outcomes like survival and 
disease progression. A consensus paper by Cohn et  al. 
[43] recommends new drug treatment in HF be assessed 
by their effect on LV remodelling. To emphasise this, 
Kramer et al. [35] performed a meta-analysis of 30 mor-
tality trials (involving 25 drugs or device interventions) 
and 88 remodelling studies and showed excellent correla-
tions between effects on LV remodelling and its impact 
on mortality. Indeed pre-clinical work has shown that 
SGLT2 inhibitors are capable of reducing LV mass and 
volume in a rat model with progressive HF [44]. Accord-
ingly, we have selected cardiac MRI measurements of LV 
EDV and LV ESV as the primary outcome measures for 
the REFORM Trial. Other measures of LV remodelling 
such as LV mass and LVEF are key secondary outcome 
measures. By ensuring the trial is adequately powered 
for all three facets of LV remodelling we will, for the first 
time in humans, determine if treatment with an SGLT2 
inhibitor be able to induce positive LV remodelling in 
diabetic patients with HF.
The metabolic effects of SGLT2 inhibitors include 
weight loss and reduced insulin resistance. Weight 
loss addresses a universal problem in the HF popula-
tion; poor effort tolerance, which establishes a vicious 
cycle that propagates DM and HF. A patient’s weight is 
a major determinant of their effort tolerance, and physi-
cal activity has repeatedly been shown to benefit patients 
with HF [45–47]. A 24  week study comparing dapagli-
flozin to placebo showed 2.5–3.5 kg weight reduction as 
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a result of the caloric loss produced by the glycosuria, 
thus potentially improving overall effort tolerance [48]. 
Besides weight, the degree of insulin resistance (IR) has 
also been demonstrated to be inversely related to exer-
cise capacity and directly related to disease severity and 
clinical outcomes; Doehner et al. had demonstrated that 
lower insulin sensitivity was associated with significantly 
lower peak oxygen consumption and LV EF. They also 
showed reduced insulin sensitivity was an independ-
ent predictor of mortality in patients with HF [49]. The 
relationship between IR and exercise capacity has also 
been demonstrated in apparently healthy individuals 
and in diabetic patients [50–52]. The mechanisms for 
this has yet to be defined, however one possible mecha-
nism could be explained by the endothelial dysfunction 
caused by the blunting of insulin-induced endothelial 
nitric oxide synthase (eNOS) as a result of IR. This in 
turn leads to impaired muscle and cardiac blood flow and 
glucose transport resulting in reduced exercise capac-
ity [53]. Improving insulin sensitivity has been shown to 
improve exercise capacity in diabetic individuals with HF 
[54, 55]. Studies utilising insulin sensitizers such as thio-
zolidinediones have shown improving insulin sensitivities 
increases exercise capacity [56]. There is yet to be simi-
lar work done around SGLT2 inhibitors, however ZDF 
rats treated with dapagliflozin [25] and empagliflozin 
[57] have shown improving insulin sensitivity in treated 
populations. Also, a randomized double blind placebo 
controlled trial using dapagliflozin also showed improved 
insulin sensitivity during hyperinsulinaemic euglycaemic 
clamping in T2DM patients [58]. By causing weight loss 
and improving insulin sensitivity, SGLT2 inhibitors could 
significantly increase the effort tolerance of patients with 
HF, thereby reducing morbidity and mortality.
The EMPA-REG Outcomes trial revealed poten-
tially beneficial effects of empagliflozin among patients 
with HF, however it is unknown if these effects are 
seen throughout the SGLT2 inhibitor class. Other car-
diovascular outcome trials such as DECLARE-TIMI 58 
(NCT: 01730534) for dapagliflozin and CANVAS (NCT: 
01032629) for canagliflozin will reveal whether or not the 
cardioprotective effects of SGLT2-inhibitor therapy is 
seen across this drug class. As described above, this study 
will be able to provide insights into the mechanism of the 
positive cardiovascular effects conferred by SGLT2 inhib-
itor therapy and may also help underpin future outcome 
trials in HF patients involving this drug class.
Limitations
Firstly this is a relatively small, single centre trial. The 
use of cardiac MRI has allowed the power of the trial 
to be preserved despite the small number of partici-
pants. However, some differences observed may still be 
the result of chance and is therefore a limitation of this 
study. Secondly heart failure is a dynamic disease, as a 
patient’s intravascular volume changes, their loop diu-
retic requirement may fluctuate. This may necessitate 
dose adjustments during the trial which could confound 
Exercise 
capacity
Weight loss
Preload 
• EDV / ESV 
•
• LV mass 
• RV volumes 
• Atrial volumes 
• VO2 Max
• VO2/kg
• Ve/V02 & Ve/VCO2
• Distance travelled 
•
• Weight 
Cardiac - MRI
CPEX & 
6MWT
BCA
Parameter Outcome
Improvement 
in 
heart failure 
Fig. 3 REFORM trial hypothesis. The figure above explains the hypothesis of the REFORM trial where reduction in pre and afterload as well as 
improvement in exercise capacity and weight loss will all contribute to improvement in heart failure. These features will be measured by cardiac 
MRI, CPEX, 6MWT and BCA to determine their exact contribution to cardiac function. CPEX cardio-pulmonary exercise test; 6MWT 6 min walk test; 
BCA body composition analysis; V02 Max Maximum oxygen consumption; Ve minute ventilation; VC02 carbon dioxide production
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the final outcome. However, every measure is taken to 
ensure blinding of the investigators is maintained and 
uniformity in the dose adjustments made.
Conclusions
HF and DM remain major clinical problems that are 
associated with increased mortality and morbidity. Ther-
apeutic options to optimize glycaemic control in DM and 
HF are limited, and only metformin appears to have ben-
eficial effects on CV outcomes. SGLT2 inhibitors could 
potentially improve LV remodelling and exercise capac-
ity in these patients, thus offering an important new 
approach to HF management in DM. If they improve 
exercise capacity and LV remodelling in HF by reduc-
ing both preload and afterload, a strong case could be 
made for a larger trial specifically in HF patients with 
DM to test if SGLT2 inhibitors really do have a mortal-
ity benefit in this unique patient group. Of course these 
drugs might, conceivably, alter fluid status in HF with-
out altering LV remodelling. We therefore, also need 
safety data on what (if anything) they do to fluid status 
in HF patients. If they behave like glitazones, they could 
increase fluid retention (and by doing so exacerbate HF). 
On the other hand, since they produce diuresis, they are 
more likely to have the opposite effect. Only by studying 
this, will we know the answer. There is currently no data 
on combining SGLT2 inhibitors and diuretics which is 
why this combination is not recommended at this point 
in time. This study will, with careful monitoring, begin 
to address this combination, and for the reasons given 
above, it is likely to be more beneficial than harmful in 
patients with HF. If this study shows that SGLT2 inhibi-
tors have the dual effect of being a diuretic and favour-
ably remodelling the LV in HF patients, then they would 
stand head and shoulders above other potential second 
line anti-diabetics for use in HF patients.
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